Mori K - Search Results

1

Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.

Kataoka M, Yamaguchi Y, Moriya Y, Sawada N, Yasuno H, Kondoh K, Evans DB, Mori K, Hayashi S. Kataoka M, et al. Among authors: mori k. Oncol Rep. 2012 Feb;27(2):303-10. doi: 10.3892/or.2011.1541. Epub 2011 Nov 9. Oncol Rep. 2012. PMID: 22076074

2

Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.

Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y. Fujimoto-Ouchi K, et al. Among authors: mori k. Cancer Chemother Pharmacol. 2007 May;59(6):795-805. doi: 10.1007/s00280-006-0337-z. Epub 2006 Oct 10. Cancer Chemother Pharmacol. 2007. PMID: 17031648

3

Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.

Sawada N, Kondoh K, Mori K. Sawada N, et al. Among authors: mori k. Oncol Rep. 2007 Oct;18(4):775-8. Oncol Rep. 2007. PMID: 17786335

4

Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.

Furugaki K, Iwai T, Shirane M, Kondoh K, Moriya Y, Mori K. Furugaki K, et al. Among authors: mori k. Oncol Rep. 2010 Nov;24(5):1141-6. doi: 10.3892/or_00000965. Oncol Rep. 2010. PMID: 20878103

5

Effect of erythropoietin on human tumor growth in xenograft models.

Kataoka M, Moriya Y, Moriguchi Y, Iwai T, Fujimoto-Ouchi K, Shirane M, Kondoh K, Mori K. Kataoka M, et al. Among authors: mori k. Mol Med Rep. 2010 Jan-Feb;3(1):95-101. doi: 10.3892/mmr_00000224. Mol Med Rep. 2010. PMID: 21472206

6

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.

Iwai T, Moriya Y, Shirane M, Fujimoto-Ouchi K, Mori K. Iwai T, et al. Among authors: mori k. Oncol Rep. 2012 Apr;27(4):923-8. doi: 10.3892/or.2011.1614. Epub 2011 Dec 30. Oncol Rep. 2012. PMID: 22209766 Free PMC article.

7

Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers.

Furugaki K, Iwai T, Kondoh K, Moriya Y, Mori K. Furugaki K, et al. Among authors: mori k. Oncol Lett. 2010 Mar;1(2):231-235. doi: 10.3892/ol_00000041. Epub 2010 Mar 1. Oncol Lett. 2010. PMID: 22966286 Free PMC article.

8

Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.

Yasuno H, Kurasawa M, Yanagisawa M, Sato Y, Harada N, Mori K. Yasuno H, et al. Among authors: mori k. Oncol Rep. 2013 Feb;29(2):451-8. doi: 10.3892/or.2012.2149. Epub 2012 Nov 27. Oncol Rep. 2013. PMID: 23229803

9

Novel models of cancer-related anemia in mice inoculated with IL-6-producing tumor cells.

Mori K, Fujimoto-Ouchi K, Onuma E, Noguchi M, Shimonaka Y, Yasuno H, Nishimura T. Mori K, et al. Biomed Res. 2009 Feb;30(1):47-51. doi: 10.2220/biomedres.30.47. Biomed Res. 2009. PMID: 19265263 Free article.

10

Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.

Yanagisawa M, Fujimoto-Ouchi K, Yorozu K, Yamashita Y, Mori K. Yanagisawa M, et al. Among authors: mori k. Oncol Rep. 2009 Aug;22(2):241-7. Oncol Rep. 2009. PMID: 19578762

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,613 results

Search Page

Filters